Valuation: Venn Life Sciences Holdings

Market Cap 51.53M 68.75M 60.34M 56.15M 96.86M 6.63B 98.34M 666M 260M 3.25B 257M 253M 11.25B P/E 2026 *
-15.1x
P/E 2027 * -114x
Enterprise Value 43.03M 57.42M 50.4M 46.89M 80.89M 5.53B 82.13M 556M 218M 2.72B 215M 211M 9.4B EV / Sales 2026 *
0.85x
EV / Sales 2027 * 0.75x
Free-Float
96.84%
Yield 2026 *
0.43%
Yield 2027 * 1.08%

Last Transcript: Venn Life Sciences Holdings

Manager TitleAgeSince
Chief Executive Officer 57 23/02/2022
Corporate Officer/Principal 39 30/06/2017
Director of Finance/CFO 63 17/10/2022
Director TitleAgeSince
Chairman 65 04/06/2025
Director/Board Member 57 12/10/2021
Director/Board Member 63 17/10/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 68.75M
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+647.65% 40.23B
-0.27%+4.45%+11.81%+60.81% 36.23B
+0.35%+0.87%+4.46%-10.31% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.44% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.10% 13.12B
-2.68%-2.49%-11.36%-34.51% 12.7B
Average +0.20%+0.83%+54.56%+107.32% 27.25B
Weighted average by Cap. +0.48%+0.91%+74.42%+137.69%

Financials

2026 *2027 *
Net sales 50.37M 67.21M 58.99M 54.89M 94.68M 6.48B 96.13M 651M 255M 3.18B 252M 247M 11B 55.23M 73.7M 64.68M 60.19M 104M 7.1B 105M 714M 279M 3.49B 276M 271M 12.06B
Net income -3.49M -4.66M -4.09M -3.8M -6.56M -449M -6.66M -45.12M -17.65M -220M -17.44M -17.11M -763M -1.03M -1.37M -1.2M -1.12M -1.93M -132M -1.96M -13.25M -5.18M -64.74M -5.12M -5.02M -224M
Net Debt -8.49M -11.33M -9.94M -9.25M -15.96M -1.09B -16.21M -110M -42.92M -536M -42.42M -41.62M -1.85B -9.93M -13.25M -11.63M -10.82M -18.67M -1.28B -18.96M -128M -50.21M -627M -49.62M -48.68M -2.17B
Logo Venn Life Sciences Holdings
hVIVO plc is a United Kingdom-based specialist early-stage drug development contract research organization (CRO) and human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base. It specializes in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its quarantine facility. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. The Company, through its subsidiary, operates an approximately 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. It also offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Company also provides industry-standard, temperature-controlled storage solutions for biological and clinical materials.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
BBB